Pregnancy

Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress

CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company…

1 year ago

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update

                  - Patient enrollment has commenced in landmark pivotal trial for lead product…

1 year ago

Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure Risk Reductions of…

1 year ago

BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)

Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to help them manage their symptoms…

1 year ago

Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France

-- Reimbursed early access program allows for patients with hypothalamic obesity in France to receive setmelanotide treatment ---- Early access…

1 year ago

United States Women Health Laboratory Testing Research Report 2023-2028: Focus on Hereditary Cancer, Reproductive Health and Infectious Diseases, Prenatal Screening and Diagnostic Testing – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "United States Women Health Laboratory Testing Market by Hereditary Cancer, Reproductive Health and Infectious Diseases, Prenatal Screening and…

1 year ago

Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc

- First of its kind, non-surgical, permanent birth control option begins enrollment in landmark trial -ATLANTA, Aug. 03, 2023 (GLOBE…

1 year ago

Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023

MIAMI, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

1 year ago

Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth

Grant Funds Will Support Proof-of-Concept Target Validation Studies for Preclinical Development of a Potential New Approach for the Prevention and…

1 year ago